Parion begins phase 1/2a clinical trial to treat dry eye disease

  • July 24, 2014

Parion announced that it enrolled the first patient in the phase 1/2a clinical trial of P-321 ophthalmic solution for the treatment of dry eye disease.

Parion said it will study the pharmacokinetics and pharmacodynamics of P-321 in the target patient population; results are expected in early 2015.

Full Story »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

More »
More »
More »
More »